Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial-Reference-Cited by-同舟云学术

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial

Published:2020-04-29 Issue:1 Volume:1 Page:133-141
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Phillips Elizabeth H.¹²^ORCID,Burton Catherine³,Kirkwood Amy A.²,Barrans Sharon³,Lawrie Anthony²,Rule Simon⁴,Patmore Russell⁵,Pettengell Ruth⁶^ORCID,Ardeshna Kirit M.⁷,Montoto Silvia⁸,Paneesha Shankara⁹,Clifton‐Hadley Laura²,Linch David C.¹⁰^ORCID,McMillan Andrew K.¹¹

Affiliation:

1. Division of Cancer Sciencesthe University of Manchester Manchester UK

2. Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer InstituteUniversity College London London UK

3. HMDS, St James's University Hospital Leeds UK

4. Plymouth University Medical School Plymouth UK

5. Haematology Department, Castle Hill Hospital Hull UK

6. Clinical Sciences Department, St George's University of London London UK

7. Haematology DepartmentUniversity College Hospital London London UK

8. Haemato‐oncology DepartmentBarts Health NHS Trust London UK

9. Haematology DepartmentHeart of England NHS Trust Birmingham UK

10. UCL Cancer InstituteUniversity College London London UK

11. Haematology DepartmentNottingham University Hospitals NHS Trust Nottingham UK